Truist Securities Downgrades Corcept Therapeutics (CORT) to Hold

Truist Securities analyst Gregory Fraser downgraded Corcept Therapeutics (NASDAQ: CORT) from Buy to Hold with a price target of $30.00.

For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.

Shares of Corcept Therapeutics closed at $28.66 yesterday.

You May Also Be Interested In

• Corcept Therapeutics (CORT) Reports Positive Results From Open-Label Portion of Phase 3 GRACE Trial
• Barclays Downgrades Addus HomeCare (ADUS) to Underweight
• Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'